PF-05212377 (SAM-760)

DRUG2 trials

Sponsors

Pfizer

Conditions

Alzheimer's DiseaseHealthy

Phase 1

Multiple Ascending Dose Study To Assess Safety, Tolerability And Pharmacokinetics Of PF-05212377 (SAM-760)

CompletedNCT01159496

Start: 2010-07-31End: 2010-12-31Updated: 2011-03-10

Phase 2

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

TerminatedNCT01712074

PfizerAlzheimer's Disease

Start: 2012-11-30End: 2015-09-30Updated: 2017-03-20

Related Papers

A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.

2018-04-0523 citations